- CA$23.13m
- CA$25.83m
- CA$0.03m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | -1,223.06 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Oct | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | 0.14 | 0.11 | 0.27 | 0.67 | 0.03 | n/a | n/a | -51.37% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).
Directors
- Howard Verrico CHM
- Christopher Hopton CFO
- Geraldine Deliencourt-Godefroy CSO
- Alex Marazzi IND
- Jason Tian IND
- Last Annual
- October 31st, 2023
- Last Interim
- April 30th, 2024
- Incorporated
- October 19th, 2006
- Public Since
- July 10th, 2007
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 256,979,505
- Address
- c/o WeWork, 595 Burrard St., VANCOUVER, V7X 1L4
- Web
- https://www.sironabiochem.com/
- Phone
- +1 6046414466
- Auditors
- DeVisser Gray LLP
Upcoming Events for SBM
Q4 2024 Sirona Biochem Corp Earnings Release
Similar to SBM
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
Kane Biotech
TSX Venture Exchange
KDA
TSX Venture Exchange
FAQ
As of Today at 23:17 UTC, shares in Sirona Biochem are trading at CA$0.09. This share price information is delayed by 15 minutes.
Shares in Sirona Biochem last closed at CA$0.09 and the price had moved by -10% over the past 365 days. In terms of relative price strength the Sirona Biochem share price has underperformed the Toronto Stock Exchange 300 Composite Index by -20.69% over the past year.
The overall consensus recommendation for Sirona Biochem is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSirona Biochem does not currently pay a dividend.
Sirona Biochem does not currently pay a dividend.
Sirona Biochem does not currently pay a dividend.
To buy shares in Sirona Biochem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.09, shares in Sirona Biochem had a market capitalisation of CA$23.13m.
Here are the trading details for Sirona Biochem:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: SBM
Based on an overall assessment of its quality, value and momentum Sirona Biochem is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sirona Biochem is CA$0.95. That is 955.56% above the last closing price of CA$0.09.
Analysts covering Sirona Biochem currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sirona Biochem. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +7.5%.
As of the last closing price of CA$0.09, shares in Sirona Biochem were trading +20.04% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sirona Biochem PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sirona Biochem's management team is headed by:
- Howard Verrico - CHM
- Christopher Hopton - CFO
- Geraldine Deliencourt-Godefroy - CSO
- Alex Marazzi - IND
- Jason Tian - IND